3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 3
1
Status
Completed
2
Terminated
1
Sponsor Class
OTHER
12
INDUSTRY
3
Study Type
Interventional
2
Observational
1
Sponsor
Cancer Type
Lymphoid
57
Other hematologic neoplasm
21
Plasma cell
14
Sarcoma
4
Myeloid
4
Dermatologic
3
Classical hematology
3
Thoracic
2
Genitourinary
2
Other solid neoplasm
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Anemia
116
Neoplasms
77
Anemia, Refractory, with Excess of Blasts
32
Myelodysplastic Syndromes
31
Leukemia, Myeloid, Acute
28
Venous Thromboembolism
25
Thrombocytopenia
24
Leukemia
22
Breast Neoplasms
22
Febrile Neutropenia
21
Neutropenia
18
Precursor Cell Lymphoblastic Leukemia-Lymphoma
17
Multiple Myeloma
15
Lymphoma
14
Hematologic Neoplasms
14
Anemia, Sickle Cell
14
Ovarian Neoplasms
12
Myeloproliferative Disorders
10
Leukemia, Lymphocytic, Chronic, B-Cell
10
Fanconi Anemia, Complementation Group D1
10
Venous Thrombosis
9
Primary Myelofibrosis
9
Lung Neoplasms
9
Leukemia, Myelomonocytic, Chronic
9
Prostatic Neoplasms
8
Lymphoma, Non-Hodgkin
8
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
8
Hodgkin Disease
8
Pulmonary Embolism
7
Hemophilia A
7
Interventions
ferric carboxymaltose
2
Tinzaparin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphoproliferative Disorders
×
Classical hematology
×
Clear all
NCT01100879
2022-05-09
AOC-MM
Vifor Pharma
Phase 4
Terminated
3 enrolled
NCT03099031
2019-12-16
PREDICARE
LEO Pharma
Completed
420 enrolled
NCT01101399
2013-12-18
FID-CHEMO
Vifor Pharma
Phase 3
Completed
19 enrolled